HK Stock Movement | TYK MEDICINES-B (02410) Surges Over 12% Intraday as Market Focuses on Core Product TY-9591 Progress

Stock News12-05

TYK MEDICINES-B (02410) rose more than 12% intraday, with gains narrowing to 7.16% by press time at HK$14.21, recording a turnover of HK$132 million. The surge follows heightened market attention on the company's core product, TY-9591 (Aidotinib), after its key Phase II clinical trial for non-small cell lung cancer (NSCLC) with brain metastasis drew significant interest at the World Conference on Lung Cancer in September.

TY-9591, a highly selective small-molecule inhibitor targeting EGFR classical mutations, completed enrollment of 224 patients for conditional approval in November 2024. The company submitted a Pre-NDA application in April 2025 and expects to file a formal New Drug Application (NDA) in Q4 2025.

Analysts note that third-generation EGFR-TKIs have become foundational in lung cancer targeted therapy, with intense R&D competition. Post-resistance to EGFR-TKIs remains a critical challenge, making next-line solutions a high-value investment focus.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment